Oncothyreon Canada Inc.
Records under this name other than patents Oncothyreon Canada Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Oncothyreon Canada Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,491,707 | Synthetic lipid-a-analogs and uses thereof Formerly held Term ended Term ended Nov 15, 2020 · From the USPTO record | Term ended | Term ended Nov 15, 2020 | From the USPTO record |
| US 8,198,400 | Vaccine for modulating between T1 and T2 immune responses Formerly held Lapsed on the fee record Ended Jun 12, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2020 | From the USPTO record |
| US 8,097,593 | Lipid A and other carbohydrate ligand analogs Formerly held Lapsed on the fee record Ended Jan 17, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2020 | From the USPTO record |
| US 9,173,929 | Mucinous glycoprotein (MUC-1) vaccine Formerly held Lapsed on the fee record Ended Nov 3, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 3, 2019 | From the USPTO record |
| US 6,544,549 | Multilamellar coalescence vesicles (MLCV) containing biologically active compounds Formerly held Term ended Term ended Sep 25, 2019 · From the USPTO record | Term ended | Term ended Sep 25, 2019 | From the USPTO record |
| US 8,871,250 | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine Formerly held Lapsed on the fee record Ended Oct 28, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 28, 2018 | From the USPTO record |
| US 6,312,718 | Vaccine for B-cell malignancies Formerly held Term ended Term ended Oct 27, 2018 · From the USPTO record | Term ended | Term ended Oct 27, 2018 | From the USPTO record |
| US 7,820,627 | Lipid A and other carbohydrate ligand analogs Formerly held Lapsed on the fee record Ended Oct 26, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 26, 2018 | From the USPTO record |
| US 7,741,297 | Immunostimulatory, covalently lipidated oligonucleotides Formerly held Lapsed on the fee record Ended Jun 22, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 22, 2018 | From the USPTO record |
| US 6,600,012 | Lipid-modified muc-1 derivatives Formerly held Term ended Term ended May 8, 2018 · From the USPTO record | Term ended | Term ended May 8, 2018 | From the USPTO record |